Blood Coagulation Factors
"Blood Coagulation Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous substances, usually proteins, that are involved in the blood coagulation process.
| Descriptor ID |
D001779
|
| MeSH Number(s) |
D12.776.124.125 D23.119
|
| Concept/Terms |
Blood Coagulation Factors- Blood Coagulation Factors
- Blood Coagulation Factor
- Factor, Blood Coagulation
- Coagulation Factor, Blood
- Coagulation Factors, Blood
- Factors, Blood Coagulation
- Coagulation Factors
- Factor, Coagulation
- Factors, Coagulation
- Coagulation Factor
- Clotting Factors
- Factors, Clotting
|
Below are MeSH descriptors whose meaning is more general than "Blood Coagulation Factors".
Below are MeSH descriptors whose meaning is more specific than "Blood Coagulation Factors".
This graph shows the total number of publications written about "Blood Coagulation Factors" by people in this website by year, and whether "Blood Coagulation Factors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 1 | 2 |
| 1996 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Blood Coagulation Factors" by people in Profiles.
-
Mishra AK, Sahu KK, Siddiqui AD, George SV. Initiation of a fixed- dose four- factor prothrombin complex concentrate protocol. J Thromb Thrombolysis. 2020 02; 49(2):332-333.
-
Epstein DS, Mitra B, Cameron PA, Fitzgerald M, Rosenfeld JV. Normalization of coagulopathy is associated with improved outcome after isolated traumatic brain injury. J Clin Neurosci. 2016 Jul; 29:64-9.
-
Chai P, Babu K. Toxin-induced coagulopathy. Emerg Med Clin North Am. 2014 Feb; 32(1):53-78.
-
Johari V, Loke C. Brief overview of the coagulation cascade. Dis Mon. 2012 Aug; 58(8):421-3.
-
Muzaffar J, Katragadda L, Haider S, Javed A, Anaissie E, Usmani S. Rituximab and intravenous immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature. Int J Hematol. 2012 Jan; 95(1):102-6.
-
Borzecki AM, Kaafarani H, Cevasco M, Hickson K, Macdonald S, Shin M, Itani KM, Rosen AK. How valid is the AHRQ Patient Safety Indicator "postoperative hemorrhage or hematoma"? J Am Coll Surg. 2011 Jun; 212(6):946-953.e1-2.
-
Balsam LB, Timek TA, Pelletier MP. Factor eight inhibitor bypassing activity (FEIBA) for refractory bleeding in cardiac surgery: review of clinical outcomes. J Card Surg. 2008 Nov-Dec; 23(6):614-21.
-
Frelinger AL, Jakubowski JA, Li Y, Barnard MR, Linden MD, Tarnow I, Fox ML, Sugidachi A, Winters KJ, Furman MI, Michelson AD. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost. 2008 Feb; 6(2):359-65.
-
Tran M, Spencer FA. Thromboepidemiology: identifying patients with heritable risk for thrombin-mediated thromboembolic events. Am Heart J. 2005 Jan; 149(1 Suppl):S9-18.
-
Kim AY, Walinsky PL, Kolodgie FD, Bian C, Sperry JL, Deming CB, Peck EA, Shake JG, Ang GB, Sohn RH, Esmon CT, Virmani R, Stuart RS, Rade JJ. Early loss of thrombomodulin expression impairs vein graft thromboresistance: implications for vein graft failure. Circ Res. 2002 Feb 08; 90(2):205-12.